Chilli slot online free.REGISTER NOW GET FREE 888 PESOS REWARDS!

Highlights & Summary

Liquid Biopsy (LBx) continued to develop through April, featuring more Medicare coverage decisions as well as research collaborations and study results.

Clinical & Regulatory

Palmetto GBA is now covering Guardant's Guardant360 Response Test, the first blood-only test using ctDNA levels to understand therapy responses in cancer patients. Palmetto GBA has coverage for other Guardant products, including the Guardant360 assay, Guardant360 TissueNext, and Guardant Reveal. Palmetto GBA also administered coverage for Epic Sciences’ 56 gene ctDNA panel for the genomic profiling of breast cancer, DefineMBC. Additionally, MDxHealth SA’s Select mdx Prostate Cancer, a urine based mRNA test to assess a patient’s risk for prostate cancer, received reimbursement for Medicare patients through Palmetto GBA’s MolDX program. As far as clinical news, NHS England began rolling out a genetic test for Lynch syndrome using a blood draw - this program guarantees genetic analysis for Lynch syndrome for those diagnosed with certain endometrial and bowel conditions.?

1 | Guardant Health Receives Medicare Coverage for Guardant360 Response to Monitor Cancer Patient Response to Immunotherapy Medicare Coverage | Guardant Health

2 | Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel Medicare Coverage | Epic Sciences

3 | Foundational LCD Covers Select mdx for Prostate Cancer Medicare Coverage | MDxHealth

Company Announcements & Product Launches

Personalis, Inc. entered a collaboration with multiple UK academic organizations to deploy NeXT Personal, an LBx assay, for the TRACERx study, a lung cancer initiative funded by Cancer Research UK. The purpose of this initiative is to promote more personalized medicine for lung cancer patients and combat the challenge of how typical imaging techniques used to understand lung cancer patients’ statuses are often limited in sensitivity. ANGLE and BioView Ltd. entered an agreement to develop an LBx CTC HER2 assay for breast cancer patients using ANGLE’s Parsortix PC1 Clinical system and Bioview’s microscopy systems in order to understand the expression of HER2 in CTCs. They will use 雅培 ’s PathVysion HER2 DNA probe kit as well. The US-based Genomic Testing Cooperative (GTC) and Japan’s Sysmex Inostics (a subsidiary of @Sysmex) entered a strategic partnership to advance therapeutic discovery and development via the commercialization of GTC’s assay services including: Solid Tumor Profile Plus, Liquid Trace Hematology Profile, Liquid Trace Solid Tumor Profile and Hematology Profile Plus. Sysmex also entered into a collaboration with Juntendo University and ThinkCyte to improve detection and treatment of chronic myelogenous leukemia (CML). The efforts hinge upon ThinkCyte’s Ghost Cytometry, an AI-driven technology to characterize and sort cells’ structures, shapes, and sizes. This month also brought about multiple partnerships to support efforts in transplantation, such as between CareDx, Inc. and Miromatix, 赛默飞世尔科技 and Devyser , and Karius and eGenesis, Inc. .?

?

1 | Personalis Joins Top UK Cancer Research Organizations to EValuate Earlier Cancer Recurrence Detection Though Groundbreaking Study Trial Collaboration | Personalis, Cancer Research UK, University College London, Francis Crick Institute

2 | ANGLE announces partnership with BioView Company Partnership | ANGLE, BioView

3 | Sysmex, GTC partner for commercialisation of assay services Company Partnership | Sysmex, GTC?

Clinical Trials & Study Results

Immunocore presented new KIMMTRAK data at AACR strongly associating on-treatment ctDNA reduction with longer overall survival (OS) in patients with metastatic uveal melanoma. Authors from 诺华 published an article presenting a classification approach to detect clonal hematopoiesis (CH) from cfDNA sequencing alone. Applied to a cohort of 4324 oncology clinical cfDNA samples, they determined 30.3% of patients have evidence of CH, and demonstrated increased inflammation in patients with CH, both systematically and in the tumor microenvironment. C2i Genomics announced preliminary study results showing ctDNA (detected by C2inform assay) can be used as a prognostic marker after neoadjuvant treatment in locally advanced rectal cancer patients to determine the need for immediate surgical resection and the potential for organ preservation. Guardant Health and Parker Institute for Cancer Immunotherapy launched a research collaboration to study the correlation between molecular cancer biomarkers and immunotherapy response, and Exai Bio also presented data on the sensitivity and specificity of its proprietary RNA- and AI-based liquid biopsy platform for NSCLC early detection at AACR.

1 | Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival ?Data Results | Immunocore

2 | Clonal Hematopoiesis Detection in Patients with Cancer Using Cell-Free DNA Sequencing Study Result | Novartis

3 | C2i Genomics study finds circulating tumor DNA can predict treatment outcomes in patients with locally advanced rectal cancer enrolled for organ preservation Preliminary Study Results | C2i Genomics, Memorial Sloan Kettering

M&A | VC | Private Equity | Legal?

Quest Diagnostics will acquire Haystack MRD? by Quest Diagnostics? , and plans to adapt Haystack’s MRD test for new clinical lab services in colorectal, breast and lung cancer indications. Quest Diagnostics will pay $300M at closing, and up to $150M in the future based on milestones. Foresight Diagnostics completes a $58.8M Series B financing round to fund clinical development and commercialization of its PhasED-seq MRD testing platform. Foresight is in ongoing litigation with Personalis over alleged MRD patent infringement. Mercy BioAnalytics, Inc. closes a $41 million Series A financing round to fund development and commercialization of the Mercy Halo test for high-risk lung cancer screening, as well as advance clinical programs in additional indications.